Fu-yi Cai

GGP modified daunorubicin plus dioscin liposomes inhibit breast cancer by suppressing epithelial–mesenchymal transition

Feng Niu, Liang Kong, Rui-jun Ju, 2020, Drug development and industrial pharmacy.

Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis

Liang Kong, Xue-min Yao, Fu-yi Cai, 2020, Drug development and industrial pharmacy.

Enhanced antitumour efficacy of functionalized doxorubicin plus schisandrin B co-delivery liposomes via inhibiting epithelial-mesenchymal transition

Liang Kong, Rui-jun Ju, Xue-min Yao, 2020, Journal of liposome research.

RPV‐modified epirubicin and dioscin co‐delivery liposomes suppress non‐small cell lung cancer growth by limiting nutrition supply

Liang Kong, Rui-jun Ju, Xue-min Yao, 2019, Cancer science.

Dual variable of drug loaded micelles in both particle and electrical charge on gastric cancer treatment

Rui-jun Ju, Xue-min Yao, Fu-yi Cai, 2020, Journal of drug targeting.

Development of R8 modified epirubicin–dihydroartemisinin liposomes for treatment of non-small-cell lung cancer

Liang Kong, Rui-jun Ju, Wei Tang, 2019, Artificial cells, nanomedicine, and biotechnology.

Enhanced antitumour efficiency of R8GD-modified epirubicin plus tetrandrine liposomes in treatment of gastric cancer via inhibiting tumour metastasis

Liang Kong, Xue-min Yao, Fu-yi Cai, 2020, Journal of liposome research.

Combination of targeted daunorubicin liposomes and targeted emodin liposomes for treatment of invasive breast cancer

Liang Kong, Rui-jun Ju, Wei Tang, 2020, Journal of drug targeting.